Tumor Necrosis Factor (TNF) Inhibitor market: : Global Industry Trends, Market Size, Leading Players and Forecast 2018-2026

SANJOSE United States - December 13, 2018 /MarketersMEDIA/ —

Market Insights
Global tumor necrosis factor (TNF) inhibitor market was estimated at US$ 43,394.4 Mn in 2017 and forecasted to reach US$ 181,139.7 by 2026 with a CAGR of 16.5% during the projection period. Only five approved TNF inhibitors control the current market namely, adalimumab, certolizumab, etanercept, golimumab and infliximab. The extensive application of these approved drugs for various autoimmune conditions ensures continuous market growth during the forecast period from 2018 to 2026. Approval of biosimilars would further add to the lucrativeness of this market. Biosimilars will intensify the market competition in TNF inhibitors market as several industrial players are currently investing in their growth. High prevalence of chronic conditions such as Crohn’s disease, ulcerative colitis, plaque psoriasis, rheumatoid arthritis & others, continuous research activities in developing target-based biologics, provision of structured reimbursement policies and growing inclination towards cost-efficient biosimilars in developing economies contribute to the remunerative growth of this market. Additionally, growing prevalence of chronic autoimmune disease such as Crohn’s disease, rheumatoid arthritis, plaque psoriasis and ulcerative colitis increase the need for target based therapies such as TNF inhibitors.

Browse the full report Tumor Necrosis Factor (TNF) Inhibitors Market Growth, Future Prospects, and Competitive Analysis, 2018 -2026 report at https://www.credenceresearch.com/report/tumor-necrosis-factor-tnf-inhibitors-market

Golimumab to exhibit fastest growth rate during the forecast period
(View this segment in full report)

Crohn’s disease to gain largest market share by 2026
(View this segment in full report)

North America Dominated in 2017 and Continues This Trend Through 2026
(View this segment in full report)

Investments in Biosimilar Development has led to Increased Competition among TNF Inhibitor Market Players

TNF inhibitors market indicates an extensive competitive pool of players with continuous investments in research activities pertaining to label expansion or development of suitable biosimilars. The key players with their biological products namely, Abbvie, Inc.’s adalimumab, UCB S.A’s certolizumab, Amgen, Inc.’s etanercept and Janssen Biotech, Inc.’s golimumab & infliximab are expected to dominate the market until their patent expiry. Growth of biosimilars would affect the growth of existing biological drugs during the projection period. Manufacturers over geographies are continuously investing in biosimilars thus improving the growth of TNF inhibitors globally. Amgen, Inc. and Boehringer Ingelheim was granted FDA approval for Humira (adalimumab) in September 2016 and August 2017 respectively. Thus, post-patent expiry of the major biologics, TNF inhibitor market is predicted to witness extensive race among the biosimilar market players. Credence Research Inc. believes that a new biologic drug with extensive label use and controlled pricing is supposed to have an opportunity in the TNF inhibitor market.

Report Scope by Segments
Tumor necrosis factor inhibitors market report covers an elaborative interpretation on the current market trends and dynamics along with qualitative analysis of the global market. The report provides an in-depth analysis of global tumor necrosis factor inhibitors market by categorizing the market based on drug type, application and geography. The preliminary objective to publish this study is to guide healthcare professionals and market stakeholders in decision making and strategic initiatives in tumor necrosis factor inhibitors market.

• Drug Type Segment (2016–2026; US$ Mn)
o Adalimumab
o Certolizumab
o Etanercept
o Golimumab
o Infliximab
o Pipeline Analysis
 Phase III Molecules
 IBI303
 HLX03
 BCD-057
 M923
 Phase I & Phase II Molecules
• Application Segment (2016–2026; US$ Mn)
o Crohn’s Disease
o Rheumatoid Arthritis
o Psoriatic Arthritis
o Plaque Psoriasis
o Ulcerative Colitis
o Ankylosing Spondylitis
o Hidradenitis Suppurativa
o Uveitis
o Juvenile Arthritis

Chapter 4. Global Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Adalimumab (Humira)
4.3. Certolizumab (Cimzia)
4.4. Etanercept (Enbrel)
4.5. Golimumab (Simponi)
4.6. Infliximab (Remicade)
4.7. Pipeline Analysis
4.7.1. Phase III Molecules (Forecast till 2026 in US$ Mn)
4.7.1.1. IBI303
4.7.1.2. HLX03
4.7.1.3. BCD-057
4.7.1.4. M923
4.7.2. Phase I & Phase II Molecules (Tabular Representation)

Chapter 5. Global Tumor Necrosis Factor Inhibitors Market, by Application, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Crohn’s Disease
5.3. Rheumatoid Arthritis
5.4. Psoriatic Arthritis
5.5. Plaque Psoriasis
5.6. Ulcerative Colitis
5.7. Ankylosing Spondylitis
5.8. Hidradenitis Suppurativa
5.9. Uveitis
5.10. Juvenile Arthritis

Chapter 6. Global Tumor Necrosis Factor Inhibitors Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America Tumor Necrosis Factor Inhibitors Market, 2016 – 2026 (US$ Mn)
6.2.1. North America Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 – 2026 (US$ Mn)
6.2.2. North America Tumor Necrosis Factor Inhibitors Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America Tumor Necrosis Factor Inhibitors Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Tumor Necrosis Factor Inhibitors Market, 2016 – 2026 (US$ Mn)
6.3.1. Europe Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 – 2026 (US$ Mn)
6.3.2. Europe Tumor Necrosis Factor Inhibitors Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe Tumor Necrosis Factor Inhibitors Market, by Country, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Tumor Necrosis Factor Inhibitors Market, 2016 – 2026 (US$ Mn)
6.4.1. Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
6.4.3. Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest Of Asia Pacific
6.5. Latin America Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
6.5.1. Latin America Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
6.5.2. Latin America Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
6.5.3. Latin America Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
6.5.3.1. Mexico
6.5.3.2. Brazil
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
6.6.1. Middle East & Africa Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
6.6.2. Middle East & Africa Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
6.6.3. Middle East & Africa Tumor Necrosis Factor Inhibitors Market, by Region, 2016-2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of Middle East & Africa

Chapter 7. Profiles
7.1. Abbvie, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Amgen, Inc.
7.3. Biocad Biopharmaceutical Co.
7.4. Boehringer Ingelheim Pharmaceuticals, Inc.
7.5. EPIRUS Biopharmaceuticals, Inc.
7.6. Innovent Biologics, Inc.
7.7. Janssen Biotech, Inc.
7.8. Merck & Co., Inc.
7.9. Novartis A.G.
7.10. Pfizer, Inc.
7.11. Shanghai Henlius Biotech, Inc.
7.12. UCB S.A.

Browse the full report Tumor Necrosis Factor (TNF) Inhibitors Market Growth, Future Prospects, and Competitive Analysis, 2018 -2026 report at https://www.credenceresearch.com/report/tumor-necrosis-factor-tnf-inhibitors-market

About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290
Website: https://www.credenceresearch.com/report/tumor-necrosis-factor-tnf-inhibitors-market

Release ID: 459294